论文部分内容阅读
目的探讨调强放疗联合与不联合卡培他滨加顺铂同步化疗治疗中晚期食管癌患者的临床疗效。方法选取2012年5月至2014年1月成都市第五人民医院收治的60例中晚期食管癌患者作为研究对象,按治疗方式分为观察组(调强放疗联合卡培他滨加顺铂同步化疗)和对照组(单纯调强放疗),比较两组患者的近期疗效与1年、2年生存率及不良反应发生情况。结果观察组患者近期疗效明显高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后1年生存率明显高于对照组,差异有统计学意义(P<0.05);观察组患者恶心、呕吐及白细胞下降、手足综合征、血小板减少发生率均明显高于对照组,差异均有统计学意义(均P<0.05)。结论在中晚期食管癌患者治疗过程中,调强放疗联合卡培他滨加顺铂行同步化疗能够使患者获得更佳疗效,并提高1年生存率,不良反应可耐受。
Objective To investigate the clinical efficacy of intensity-modulated radiotherapy combined with and without capecitabine plus cisplatin in the treatment of advanced esophageal cancer patients. Methods Sixty patients with advanced esophageal cancer admitted to the Fifth People’s Hospital of Chengdu City from May 2012 to January 2014 were selected as study subjects and divided into observation group (IMRT plus capecitabine plus cisplatin Chemotherapy) and control group (melatonin alone). The short-term curative effect, 1-year and 2-year survival rate and adverse reactions of the two groups were compared. Results The short-term curative effect of the observation group was significantly higher than that of the control group (P <0.05). The 1-year survival rate of the observation group was significantly higher than that of the control group (P <0.05) The incidence of nausea, vomiting and leukopenia, hand-foot syndrome and thrombocytopenia were significantly higher in the patients than in the control group (all P <0.05). Conclusions In the treatment of patients with advanced esophageal cancer, IMRT combined with capecitabine plus cisplatin can achieve better efficacy and improve 1-year survival rate with tolerable adverse reactions.